Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on PCSK9 Inhibitors (Feb 2017)

Posted by Matt Breese on Feb 27, 2017

Find me on:

According to our recent payer coverage analysis for PCSK9 inhibitors, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of recent market access shows limited shifts in overall payer pharmacy benefit coverage. With a limited set of treatments, Medicare coverage is still the most restricted by far.
mmit-reality-check-pcsk9-q12017.png

Source: MMIT data as of Q1 2017

Trends:  Recent news related to PCSK9 products shows some key trends in this market. As expected, the small target population for PCSK9s results in a low volume of utilization. Due to the high cost and lack of long-term outcomes data, some prescribers hesitate to prescribe these products just yet. The largest PBMs, like Express Scripts, develop programs that combine discounts and create a spending cap for participating payers, which also serves to throttle utilization.

In the full Reality Check on PCSK9 inhibitors below, MMIT's team of experts takes a deeper look into the clinical characteristics, drug market access and payer coverage to summarize key findings within the class.

To read the full Reality Check on PCSK9s with key findings on clinical characteristics, PCSK9 drug market access and payer coverage, please click on the button below: 

reality-check-thumbnail-v1-1.png

View Reality Check

Topics: Specialty, Market Access, Branding & Marketing